Issue link: https://viewer.e-digitaledition.com/i/42856
which the FDA recently approved. While vemurafenib attacks a specific genetic mutation that speeds up tumor growth, ipilimumab uses the body's immune sys- tem to fight melanoma. Although neither is a cure, both are expected to extend life expectancy. "Ipi l imumab was approved in March 2011 and is now sold under the name Yervoy. This antibody targets the immune system, making it more reactive, thus working against melanoma," says Dr. Agarwala. "Patients who receive this drug are more likely to see their tumors shrink and may live longer. Most tumors don't come back for at least four to five years. While this drug does not claim to benefit everyone, it provides a survival advantage." During the nationwide Stage 3 clinical trial, ipilimumab was offered to 600 randomized melanoma patients either through an antibody, vaccine or a combi- nation of both. The results concluded that patients who received the drug in various forms lived longer than those who did not. "When patients undergo a clinical trial, they are active and informed participants in their care. While there is always a risk associated with testing a new drug, patients receive the best standard of care and are monitored closely," says Dr. Agarwala. A CLOSER LOOK AT OUR PHYSICIAN SANJIV S. AGARWALA, M.D., Chief Medical Oncologist and Hematologist at St. Luke's Hospital & Health Network, and Professor of Medicine at Temple University + Clinical Expertise: hematology and oncology + Board Certification: American Board of Internal Medicine in medicine oncology and hematology + Education: University of Bombay, Bombay, India Sanjiv S. Agarwala, M.D., "The trials that we conduct are ethical, safe and truly the best way to receive optimal treatments." Dr. Agarwala continues to work as the principal clinical investigator and oversees the care of almost all of the patients he treats. St. Luke's continues to network with Temple University in making clinical trials possible. To learn more about available melanoma treatments at St. Luke's, visit slhn.org, search "Our Major Services," select "Cancer" and then "Melanoma." n + K.E.M. Hospital, University of Bombay, Bombay, India — general medicine internship + Residency: University of Pittsburgh School of Medicine, Pittsburgh, PA — general medicine + Fellowship: University of Pittsburgh School of Medicine, Pittsburgh, PA — hematology-oncology Professional organizations and scientific societies: + American Association for Cancer Research + American Society of Clinical Oncology + Eastern Cooperative Oncology Group + American Society of Head and Neck Surgery A VIABLE ALTERNATIVE TO CHEMOTHERAPY ACCORDING TO SCIENTISTS at the annual meeting of the American Society of Clinical Oncology, melanoma patients increase their survival rate by taking the drug vemurafenib rather than undergoing chemotherapy. Recently approved by the U.S. Food and Drug Administration, vemurafenib is a BRAF- inhibitor for people with BRAF V600E mutation-positive metastatic melanoma. With approximately 40% to 60% of all melanoma patients carrying the BRAF mutation, researchers found a 74% reduction in the progression of the disease in those who take vemurafenib. They have also found that when the medication is taken orally, patients can begin seeing benefits of the drug in a matter of 72 hours. "The fact that we have discovered a drug that has a positive effect on approximately half of melanoma patients is a huge step in the right direction," says Sanjiv S. Agarwala, M.D., Chief of Medical Oncology and Hematology at St. Luke's Hospital & Health Network. "This drug is going to make a huge difference in the lives of melanoma patients around the world." MDNEWS.COM MD NEWS Eastern Pennsylvania/NW New Jersey | 17 + International Society of Biological Therapy + European Society of Medical Oncology

